title: Monoclonal gammopathy of undetermined significance: a consensus statement.
abstract: On February 25, 2009, a panel of international experts on plasma cell dyscrasia and skeletal disease met to discuss monoclonal gammopathy of undetermined significance (MGUS). This non-malignant B-cell disorder is the most common plasma cell dyscrasia and is associated with an increased risk of developing serious B-cell disorders. Individuals with MGUS also have an increased risk of osteoporosis and osteopenia associated with an increased likelihood of developing fractures especially in the vertebral column, peripheral neuropathy and thromboembolic events. The goal of the meeting was to develop a consensus statement regarding the appropriate tests to screen, evaluate and follow-up patients with MGUS. The panel also addressed the identification and treatment of MGUS-related skeletal problems, thromboembolic events and neurological complications. The following consensus statement outlines the conclusions and marks the first time that a consensus statement for the screening and treatment of MGUS has been clearly stated.
authors.affiliation: Institute for Myeloma & Bone Cancer Research, West Hollywood, CA 90069, USA. jberenson@imbcr.org
authors.forename: James R
authors.initials: JR
authors.lastname: Berenson
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Anderson
authors.forename: Robert A
authors.initials: RA
authors.lastname: Audell
authors.forename: Ralph V
authors.initials: RV
authors.lastname: Boccia
authors.forename: Morton
authors.initials: M
authors.lastname: Coleman
authors.forename: Meletios A
authors.initials: MA
authors.lastname: Dimopoulos
authors.forename: Matthew T
authors.initials: MT
authors.lastname: Drake
authors.forename: Rafael
authors.initials: R
authors.lastname: Fonseca
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Harousseau
authors.forename: Douglas
authors.initials: D
authors.lastname: Joshua
authors.forename: Sagar
authors.initials: S
authors.lastname: Lonial
authors.forename: Ruben
authors.initials: R
authors.lastname: Niesvizky
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
authors.forename: G David
authors.initials: GD
authors.lastname: Roodman
authors.forename: Jesus F
authors.initials: JF
authors.lastname: San-Miguel
authors.forename: Seema
authors.initials: S
authors.lastname: Singhal
authors.forename: Donna M
authors.initials: DM
authors.lastname: Weber
authors.forename: Maurizio
authors.initials: M
authors.lastname: Zangari
authors.forename: Eric
authors.initials: E
authors.lastname: Wirtschafter
authors.forename: Ori
authors.initials: O
authors.lastname: Yellin
authors.forename: Robert A
authors.initials: RA
authors.lastname: Kyle
mesh_terms: D000368:Aged; D001851:Bone Diseases, Metabolic / Q000175:diagnosis / Q000209:etiology; D002471:Cell Transformation, Neoplastic; D018450:Disease Progression; D006801:Humans; D008134:Long-Term Care / Q000379:methods / Q000592:standards; D008403:Mass Screening / Q000379:methods / Q000458:organization & administration; D008875:Middle Aged; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy / Q000209:etiology; D011379:Prognosis; D012307:Risk Factors